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Thomas Werge3,4,6,7, Saskia P. Hagenaars1,5, Buhm Han8, David Porteous 9,10, Archie Campbell9,11, Toni-Kim Clarke2,
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Abstract
Depression is a common and clinically heterogeneous mental health disorder that is frequently comorbid with other
diseases and conditions. Stratification of depression may align sub-diagnoses more closely with their underling
aetiology and provide more tractable targets for research and effective treatment. In the current study, we investigated
whether genetic data could be used to identify subgroups within people with depression using the UK Biobank.
Examination of cross-locus correlations were used to test for evidence of subgroups using genetic data from seven
other complex traits and disorders that were genetically correlated with depression and had sufficient power (>0.6) for
detection. We found no evidence for subgroups within depression for schizophrenia, bipolar disorder, attention
deficit/hyperactivity disorder, autism spectrum disorder, anorexia nervosa, inflammatory bowel disease or obesity. This
suggests that for these traits, genetic correlations with depression were driven by pleiotropic genetic variants carried
by everyone rather than by a specific subgroup.
Introduction
Depression is a common mental health disorder char-
acterised by persistent feelings of sadness or a loss of
interest in day-to-day activities lasting for at least a 2-
week period. These feelings can be accompanied by
tiredness, changes in appetite, changes in sleep patterns,
reduced concentration, feelings of worthlessness or
hopelessness and thoughts of self-harm or suicide.
Zimmerman et al.1 found that there were 170 different
symptom profiles amongst 1566 participants diagnosed
with major depressive disorder from the Rhode Island
MIDAS project. This variety of different symptom
profiles suggest that depression is highly hetero-
geneous2. Depression is also comorbid with many dis-
eases including cancer3, cardiovascular disease4 and
other psychiatric illnesses5. Stratification of depression,
to address heterogeneity and comorbidity, may aid in
providing valuable aetiological insights and improve
treatment efficacy.
Studies aimed at stratifying depression have examined
differences between melancholic and atypical depression6,
differences between the sexes and recurrence of the dis-
order7 and used data from other traits, such as neuroti-
cism8 and social contact9 to stratify depression. Twin-
based studies10 and genome-wide association studies11,12
have shown depression to be heritable and genetically
correlated with a number of other traits and disorders.
This shared genetic component could be due to pleio-
tropic variants shared across all individuals but could also
be as a result of a subgroup for the other trait within
depression cases. For example, there is a genetic corre-
lation of 0.33 (standard error= 0.03) between depression
and bipolar disorder13. If this genetic correlation was due
to pleiotropy, then several of the bipolar disorder variants
would be carried by most depression cases. However, if
this correlation was due to a subgroup, then a greater
proportion of the bipolar disorder variants would only be
carried by individuals in this subgroup. A subgroup could
arise where there is a causal association, a shared
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molecular pathway, a misclassification between the traits,
or an ascertainment bias in the diagnosis of depression.
For the current study, BUHMBOX (Breaking Up Het-
erogeneous Mixture Based On cross(X)-locus correla-
tions)14 was used to determine whether there was
evidence of a subgroup within depression that was
genetically more similar to other traits. BUHMBOX uses
variants associated with a subgroup trait to calculate
weighted pairwise correlations of risk allele dosages
within depression cases and controls, adjusted for effect
size and allele frequency. Where there is a subgroup
amongst depression cases that carry a greater proportion
of the risk alleles for the non-depression trait, there will be
consistent positive pairwise correlations between those
variants (as illustrated in Fig. 1). BUHMBOX then cal-
culates a P-value based on the likelihood of the observed
pairwise correlations between variants.
Two definitions of depression were assessed in the UK
Biobank15, one based on the Composite International
Diagnostic Interview Short Form (CIDI-SF)16 and the
other based on a broader help-seeking definition (broad
depression)12. Since many traits are genetically correlated
with depression13, a power calculation was performed to
determine traits with sufficient power to detect a sub-
group. Power is determined by the number of depression
cases, the size of any subgroup within depression cases,
the number of associated variants tested from the sub-
group trait and the effect sizes of these variants. We tested
sufficiently powered traits for evidence of a subgroup in
depression cases using BUHMBOX v0.3814.
Materials and methods
UK Biobank cohort
The UK Biobank is a population-based cohort of
501,726 individuals with imputed genome-wide data for
93,095,623 autosomal genetic variants15. A genetically
homogeneous sample of 462,065 individuals was identi-
fied using the first two principal components from a 4-
means clustering approach. A total of 131,790 individuals
were identified as being related up to the third degree
(kinship coefficients >0.044) using the KING toolset17 and
were removed from the sample. For these related
Fig. 1 Comparison of the genetic architecture for whole-group pleiotropy and for a subgroup. Illustration of pairwise correlations between
variants for a whole-group pleiotropy, where most depression cases carry a few variants associated with a non-depression trait and b a subgroup
within depression cases ( ), where just the subgroup carry many of the non-depression trait variants. A tick indicates a depression case individual is a
carrier of that non-depression variant.
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individuals a genomic relationship matrix was calculated
to enable the identification of one individual from each
related group that could be reinstated. This allowed the
reintroduction of 55,745 individuals providing an unre-
lated sample of 386,020 individuals.
UK Biobank depression phenotypes
Two depression phenotypes were assessed for evidence
of subgroups in UK Biobank. Both phenotypes were
restricted to only those individuals that had completed
the online mental health questionnaire (n= 109,049).
The first phenotype analysed was based on the Compo-
site International Diagnostic Interview Short Form
(CIDI-SF)18 as used by Davis et al.16 to provide a lifetime
instance measure of depression in the UK Biobank. Davis
et al.16 provide a more in-depth description of this CIDI-
SF phenotype, but in summary cases were defined as
having:
● At least one core symptom of depression (persistent
sadness (Data-Field: 20446) or a loss of interest
(Data-Field: 20441)) for most or all days over a two-
week period which were present “most of the day” or
“all of the day”.
● Plus at least another four non-core depressive
symptoms with some or a lot of impairment
experienced during the worst 2-week period of
depression or low mood.
The non-core depressive symptoms that were included
in this assessment of the worst episode of depression
were: Feelings of tiredness (Data-Field: 20449), Weight
change (Data-Field: 20536), Did your sleep change? (Data-
Field: 20532), Difficulty concentrating (Data-Field: 20435),
Feelings of worthlessness (Data-Field: 20450) and
Thoughts of death (Data-Field: 20437). Cases that self-
reported another mood disorder were excluded. Controls
were determined by not having at least one core symptom
of depression or not endorsing at least another four non-
core depressive symptoms if at least one core symptom
was endorsed. This provided 25,721 CIDI-SF cases and
61,894 controls.
A second depression phenotype within the UK Biobank
cohort was also examined using the broad depression
definition from Howard et al.12 with detailed information
provided in that paper. In summary, cases had sought help
for nerves, anxiety, tension or depression from either a
general practitioner or a psychiatrist (Data-Field: 2090
and Data-Field: 2100), whereas controls had not. Cases
were supplemented with an additional 132 individuals
identified as having a primary or secondary International
Classification of Diseases (ICD)-10 diagnosis of a
depressive mood disorder from linked hospital admission
records (Data-Field: 41202 and Data-Field: 41204). Parti-
cipants identified with bipolar disorder, schizophrenia or
personality disorder and those reporting a prescription for
an antipsychotic medication were removed. This provided
a total of 36,790 broad depression cases and 70,304 con-
trols. The phenotypic correlation between the CIDI-SF
depression phenotype and the broad depression pheno-
type was 0.61 with the number of cases and controls
shared across the two definitions shown in Supplementary
Table 1.
Sensitivity analysis
To allow a direct comparison between the two defini-
tions of depression, the main analysis was restricted to
those UK Biobank participants that had completed the
mental health questionnaire. To examine whether the full
UK Biobank sample provided greater power for the
detection of subgroups, a sensitivity analysis was con-
ducted using the broad depression phenotype (113,769
cases and 208,811 controls).
Traits examined as subgroups within depression
We selected traits genetically correlated with depression
(false discovery rate corrected, q < 0.01) in Howard et al.13
to test as subgroups within depression, which included
anthropomorphic, autoimmune, life course, cardiovas-
cular and other psychiatric traits. For each trait, there was
a requirement that publicly available summary statistics
were available and that the UK Biobank was not included
in that study due to potential confounding effects (Sup-
plementary Table 2).
The BUHMBOX power calculation test v0.114 was used
to determine whether there was sufficient power to detect
a subgroup for each depression correlated trait and to
identify the optimum variant selection criterion (P < 5 ×
10−8, P < 10−6 or P < 10−4). The power calculation was
conducted separately for the CIDI-SF depression pheno-
type and the broad depression phenotype. Variants from
the summary statistics for each subgroup trait were
examined in the UK Biobank. Variants that had a call rate
<0.99, were out of Hardy–Weinberg equilibrium (P <
10−10), had a hard call threshold <0.25, or had a minor
allele frequency <0.01 were excluded. BUHMBOX
requires that all variants are available for all individuals
and therefore individuals with a call rate <1 were
removed. To identify independently segregating variants,
clumping was conducted in PLINK v1.90b419 using an r2
value of 0.01 across a 3-Mb window in either CIDI-SF or
broad depression control individuals, respectively.
For the power analysis the approach used in Han
et al.14 was followed, with 1000 simulated iterations run
for each trait, the proportion of individuals in the sub-
group was set to the genetic risk score beta coefficient
(which represents the upper bound of the heterogeneity
proportion) and a nominal subgroup P-value of 0.05 was
used. Power analyses were used to identify the optimum
variant selection criterion that provided the greatest
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power for each subgroup trait. Where power was the
same across variant selection criteria, the strictest variant
selection criterion was selected as the optimum. Variants
with P < 10−4 were not publicly available for Squamous
Cell Lung Cancer or Lung Cancer and so P < 10−5 was
used instead. Only those traits that had a power >0.6
(using the optimum variant selection criterion) were
selected to be tested for evidence of a subgroup within
depression. A linear regression was used to examine the
association between power and the heritability of each
subgroup trait and the genetic correlation each subgroup
trait shares with depression.
Testing for subgroups within depression
For the traits that had power >0.6, variants meeting the
optimum variant selection criterion were extracted from
the UK Biobank. The same quality control thresholds and
method to identify independently segregating variants as
used as previously in the power analysis were applied.
BUHMBOX v0.3814 was used to examine shared risk
alleles for each subgroup trait within CIDI-SF depression
and broad depression. BUHMBOX uses the positive
correlations between risk allele dosages in cases to
determine whether any sharing of risk alleles is driven by
all individuals (whole-group pleiotropy) or by a subset of
individuals (Fig. 1). The likelihood of observing such
positive correlations are used to determine the subgroup
P-values.
Sex, age, genotyping array and the first 20 principal
components were fitted as covariates in the subgroup
analysis. Bonferroni correction was used to account for
the multiple testing of subgroup traits, with P-values
<7.14 × 10−3 (0.05/7) or <0.01 (0.05/5) deemed significant
for CIDI-SF or broad depression, respectively. No multi-
ple testing correction was applied for the two depression
definitions analysed. In the sensitivity analysis, using the
full UK Biobank sample, a P-value <8.33 × 10−3 (0.05/6)
was deemed significant for broad depression.
Results
Power analyses of potential subgroups traits
To determine whether there was sufficient power (>0.6)
to detect a subgroup and identify the optimum variant
selection criterion (P < 5 × 10−8, P < 10−6 or P < 10−4) for
each trait the BUHMBOX power calculation test v0.114
was used. The genetic risk score beta coefficients, repre-
senting an upper bound for heterogeneity proportion, for
each trait within either Composite International Diag-
nostic Interview Short Form (CIDI-SF) depression or
broad depression are provided in Supplementary Table 3.
The results of the power analysis for detecting a subgroup
for 25 available traits within the two depression defini-
tions are provided in Table 1. Five traits had power >0.6
across both the CIDI-SF depression and broad depression
definitions: bipolar disorder20, attention deficit/hyper-
activity disorder21, autism spectrum disorder22, anorexia
nervosa23 and inflammatory bowel disease24. There were
two further traits, schizophrenia25 and obesity 326, that
had power >0.6 for detection of a subgroup in CIDI-SF
depression.
A linear regression of subgroup power on the herit-
ability of each subgroup trait and the genetic correlation
shared with depression revealed that heritability was
positively associated with power (CIDI-SF depression P-
value= 5.32 × 10−4; broad depression P-value= 3.48 ×
10−4), but genetic correlation with depression was not
associated with power (CIDI-SF depression P-value=
0.57; broad depression P-value= 0.21).
The sensitivity analysis, analysing broad depression in
the full UK Biobank sample, provided a small increase in
power for the majority of subgroups compared to broad
depression amongst individuals who had completed the
mental health questionnaire. Six traits had power >0.6:
bipolar disorder, attention deficit/hyperactivity disorder,
autism spectrum disorder, anorexia nervosa, inflamma-
tory bowel disease and schizophrenia (Supplementary
Table 4).
Testing for subgroups within depression
BUHMBOX v0.3814 was used to test seven traits for
evidence of a subgroup within CIDI-SF depression, five
traits within broad depression and six traits in the sensi-
tivity analysis. The results of the subgroup for CIDI-SF
and broad depression analyses are provided in Table 2 and
the results of the sensitivity analysis are provided in
Supplementary Table 5. None of the traits examined
provided evidence of a genetic subgroup within depres-
sion (P > 0.05) before correction for multiple testing.
Discussion
Depression is a heterogeneous mental health disorder
and is comorbid with many other diseases and illnesses.
Over the last few years, valuable progress has been made
in understanding the underlying genetic architecture of
depression11,13,27. Furthermore, stratifying depression
using genetic data remains a key goal within the psy-
chiatric genetics community28 and should lead to
improved classification of mental health conditions and
more efficacious treatment for patients. Machine learn-
ing29,30 and polygenic risk score6,31 approaches offer
possible methods for stratification in mental health. In the
current study, we used BUHMBOX14 to identify whether
traits that were genetically correlated with depression
were correlated due to a subgroup, i.e. the correlation was
driven by a subset of depressed individuals who had a
greater genetic loading for the trait. Evidence of a sub-
group within depression may provide future opportunities
for stratifying the disease.
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To allow a direct comparison between stricter and
broader definitions of depression two phenotypes were
examined. For the subgroups examined across both defi-
nitions (and using the same variant selection criteria),
CIDI-SF depression had greater upper bounds for the
heterogeneity proportion for bipolar disorder, autism
spectrum disorder and anorexia nervosa, whereas broad
depression had a greater upper bound for the hetero-
geneity proportion for attention deficit/hyperactivity dis-
order. The heterogeneity upper bound was assessed using
genetic risk scores, which suggests that a stricter defini-
tion of depression shared a larger genetic component with
bipolar disorder, autism spectrum disorder and anorexia
nervosa and the broader definition shared a genetic
component with attention deficit/hyperactivity disorder.
This supports the observations of Cai et al.32 for bipolar
disorder, autism spectrum disorder and attention deficit/
hyperactivity disorder using genetic correlations
(although they did not assess anorexia nervosa). As there
were no significant subgroups found within depression,
no firm conclusions can be drawn on the effectiveness of
using stricter or broader definitions to stratify depression.
The lack of evidence for subgroups within depression
for the seven traits examined with BUHMBOX, suggest
Table 1 Power analysis for detecting a subgroup for 25 traits within either Composite International Diagnostic
Interview Short Form (CIDI-SF) depression or broad depression in the UK Biobank.
Subgroup trait PubMed ID Optimum variant selection
criterion
Power Optimum variant selection
criterion
Power
CIDI-SF depression Broad depression
Neuroticism 24,828,478 <10−4 0.137 <10−4 0.120
Schizophrenia 25,056,061 <10−6 0.607 <10−6 0.306
Bipolar disorder 29,906,448 <10−4 0.912 <10−4 0.727
Attention deficit/hyperactivity disorder 30,478,444 <10−4 0.912 <10−4 0.992
Autism spectrum disorder 30,804,558 <10−4 1 <10−4 1
Anorexia nervosa 28,494,655 <10−4 1 <10−4 1
Triglyceride level 24,097,068 <10−4 0.183 <5 × 10−8 0.131
Coronary artery disease 26,343,387 <10−4 0.229 <5 × 10−8 0.071
Crohn’s disease 26,192,919 <10−4 0.193 <10−4 0.271
Inflammatory bowel disease 28,067,908 <10−4 0.706 <10−6 0.665
Waist to hip ratio 25,673,412 <10−4 0.070 <5 × 10−8 0.076
Body fat percentage 26,833,246 <10−6 0.057 <10−6 0.067
Waist circumference 25,673,412 <10−4 0.107 <10−4 0.070
Overweight 23,563,607 <10−4 0.131 <5 × 10−8 0.068
Obesity 1 23,563,607 <10−4 0.199 <10−6 0.089
Obesity 3 23,563,607 <10−4 0.794 <10−4 0.196
Body mass index 25,673,413 <10−4 0.101 <10−4 0.073
Age of menarche 25,231,870 <10−4 0.451 <5 × 10−8 0.081
Age of natural menopause 26,414,677 <10−4 0.407 <10−4 0.220
Years of schooling 25,201,988 <10−4 0.105 <10−4 0.089
College completion 25,201,988 <10−4 0.248 <10−4 0.160
Ever smoked 20,418,890 <10−4 0.081 <10−4 0.134
Age of smoking initiation 20,418,890 <10−4 0.061 <10−4 0.062
Squamous cell lung cancera 28,604,730 <10−5 0.078 <5 × 10−8 0.085
Lung cancera 28,604,730 <10−5 0.123 <10−6 0.137
PubMed identifiers (PubMed ID) for the 25 traits are provided. Bold values indicate that power was > 0.6. The optimum variant selection criterion that maximised
power for the subgroup traits are provided.
aVariants with P < 10−4 were not publicly available for Squamous Cell Lung Cancer or Lung Cancer and so variants with P < 10−5 were tested instead.
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that the previously reported genetic correlations13 were
the result of pleiotropy, i.e. a genetic variant is associated
with multiple phenotypes. Pleiotropy can result from
either horizontal pleiotropy (where a variant has direct
effects on multiple phenotypes) or vertical pleiotropy
(where a variant has an effect on a phenotype, then this
phenotype influences further traits downstream)33. To
assess the presence of vertical pleiotropy a technique
known as Mendelian randomisation34 can be used. This
technique has been applied previously to depression and
the traits examined with BUHMBOX, and no evidence of
vertical pleiotropy was found13. This indicates that the
genetic correlations between depression and the seven
traits examined as subgroups are likely due to horizontal
pleiotropy. Gaining a greater understanding of the bio-
logical mechanisms associated with pleiotropic variants
could be informative for improving our comprehension
and treatment for both depression and the correlated
traits.
A sensitivity analysis was conducted to investigate
whether additional power for detection of subgroups
within broad depression could be obtained by analysing
the full UK Biobank sample (n= 322,580) compared to
the subsample that had completed the mental health
questionnaire (n= 109,049). Decreased power was
observed for some subgroup traits using the full sample
which was due to lower heterogeneity proportions (based
on the genetic risk score beta coefficient) and fewer
genetic variants available for analysis (as all variants are
required to be known and so fewer were available in the
full sample). For most subgroup traits greater power was
available using the full sample, however most were still
underpowered to run the subgroup analysis. Schizo-
phrenia was the only subgroup trait that sufficiently
increased in power to exceed the >0.6 threshold, although
no evidence of a subgroup was found. The average
increase in power using the full sample compared to the
mental health questionnaire subsample was only 0.06.
However, larger genome-wide association studies of the
currently underpowered traits could allow their re-
examination as subgroups within depression in the
future. The power to detect a subgroup for a trait was also
influenced by the trait’s heritability, but not its genetic
correlation with depression. Therefore, there is the
potential to assess additional highly heritable traits where
a feasible subgroup may exist within depression.
The limitations of the current study include selection
bias, whereby particular individuals are more likely to
participate in population-based cohorts or complete
additional assessments, such as the online mental health
questionnaire. Participants of the UK Biobank are heal-
thier and from less deprived areas than the general
population35 and those that completed the mental health
questionnaire had a lower genetic predisposition to severe
depression than those who did not36. UK Biobank parti-
cipants that had either a self-reported or a hospital diag-
nosis of schizophrenia or bipolar disorder were excluded
in the current analysis, which may limit the potential for
identifying subgroups for these disorders. Most of the
traits that are genetically correlated with depression were
Table 2 Evidence of a subgroup from traits tested within either Composite International Diagnostic Interview Short
Form (CIDI-SF) depression or broad depression in the UK Biobank.
Depression definition Subgroup trait Variants βGRS Depression cases/controls Subgroup
P-value
CIDI-SF Schizophrenia 180 0.077 15,311/36,811 0.42
Bipolar disorder 436 0.062 8140/19,466 0.62
Attention deficit/hyperactivity disorder 342 0.028 8522/21,030 0.11
Autism spectrum disorder 242 0.057 13,138/31,598 0.12
Anorexia nervosa 169 0.016 16,024/38,388 0.47
Inflammatory bowel disease 954 7.37 × 10−3 2186/5265 0.46
Obesity 3 61 0.038 22,096/53,312 0.55
Broad Bipolar disorder 435 0.041 11,531/22,186 0.60
Attention deficit/hyperactivity disorder 342 0.034 12,345/23,844 0.07
Autism spectrum disorder 242 0.051 18,802/36,000 0.15
Anorexia nervosa 169 7.87 × 10−3 22,946/43,644 0.79
Inflammatory bowel disease 219 8.02 × 10−3 22,738/43,355 0.64
The number of individuals classified as depression cases and depression controls is provided. The number of variants assessed and the genetic risk score beta
coefficient (βGRS, representing the upper bound of the heterogeneity proportion) using the optimum variant selection criterion for that trait (as provided in Table 1).
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not included in the subgroup analysis due to a lack of
power (≤0.6). As increasing large genome-wide associa-
tion studies become available, a greater number of var-
iants will meet the required selection criteria, allowing
additional traits to be tested for evidence of a subgroup
within depression.
Depression is both polygenic and heterogeneous and
stratification of the disorder may lead to improvements in
treatment outcomes. We examined 25 traits genetically
correlated with depression using individuals that had
completed the UK Biobank mental health questionnaire.
There were seven traits sufficiently powered to be tested as
subgroups within CIDI-SF depression and five traits tested
as subgroups within broad depression, although none of
these provided evidence for a genetic subgroup within
depression. Alternative methodologies for stratification of
depression could also be examined (i.e. polygenic risk
scores and cluster analysis) along with consideration of
other potential stratifiers (i.e. depression severity, depres-
sive symptoms and antidepressant treatment response).
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